Geode Capital Management LLC Purchases 50,399 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Geode Capital Management LLC lifted its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 0.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,432,384 shares of the biotechnology company's stock after purchasing an additional 50,399 shares during the quarter. Geode Capital Management LLC owned 2.30% of ADMA Biologics worth $93,187,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. National Bank of Canada FI bought a new position in ADMA Biologics during the 3rd quarter valued at about $35,000. GAMMA Investing LLC lifted its position in ADMA Biologics by 106.6% during the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 967 shares during the period. Mark Sheptoff Financial Planning LLC purchased a new stake in ADMA Biologics in the fourth quarter worth approximately $35,000. Vision Financial Markets LLC purchased a new stake in ADMA Biologics in the fourth quarter worth approximately $51,000. Finally, AlphaQuest LLC bought a new stake in ADMA Biologics in the 4th quarter worth approximately $84,000. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Stock Performance

Shares of ADMA stock traded up $0.90 during mid-day trading on Tuesday, reaching $21.81. 4,788,683 shares of the company's stock traded hands, compared to its average volume of 3,580,892. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The firm has a market capitalization of $5.16 billion, a PE ratio of 77.89 and a beta of 0.53. ADMA Biologics, Inc. has a 12 month low of $5.91 and a 12 month high of $23.64. The firm has a 50 day moving average price of $17.86 and a two-hundred day moving average price of $18.16.

Remove Ads

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 price objective on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.